Last reviewed · How we verify

NCT04642989

The Effect of Facial Effleurage on Acute Rhinosinusitis

Completed NA Last updated 24 November 2020
What this trial tests

NA trial testing Sham Treatment in Rhinosinusitis Acute in 138 participants. Completed in 1 September 2020.

Timeline
1 September 2018
Primary endpoint
1 September 2020
1 September 2020

Quick facts

Lead sponsorEdward Via Virginia College of Osteopathic Medicine
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment138
Start date1 September 2018
Primary completion1 September 2020
Estimated completion1 September 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Edward Via Virginia College of Osteopathic Medicine

Who can join

Adults 18 to 69, any sex, with Rhinosinusitis Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rhinosinusitis accounts for 12% of the total antibiotic prescriptions filled in the United States annually; however, the majority of rhinosinusitis cases have been proposed to have a viral etiology, or are capable of spontaneously resolving. This overuse of antibiotics is contributing to the development of antibiotic-resistant human pathogenic bacteria, and increasing patient mortality to previously easily cured diseases. This is also causing an unnecessary financial burden especially for uninsured, rural families. Facial Effleurage (FE) is an osteopathic manipulative therapy that allows physicians an alternative therapy to prescribing antibiotics; however, the only scientific literature on the technique is weak in design and execution. This will be a randomized, placebo-controlled clinical trial to test the ability of FE to reduce symptom severity over time, reduce the cellular infiltrate into the nasal cavity, and to more quickly resolve the symptoms of rhinosinusitis compared to antibiotic treatment. This methodical approach to the efficacy of FE has the potential to impact the treatment recommendations of physicians immediately, and to convince more physicians to prescribe less antibiotics and rely more heavily on FE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sham Treatment

Trials testing the same drug.

Other recruiting trials for Rhinosinusitis Acute

Currently open trials in the same condition.

Other Edward Via Virginia College of Osteopathic Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04642989.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing